Figure 5.

Mydgf promotes heart regeneration in adult mice. (A) Schematic diagram showed the experimental design for B-L. (B and C) Masson's staining elucidated the infarcted area in wild-type (WT) adult mice treated with PBS/Mydgf at 21 days post infarction (dpi). Statistical analysis of fibrotic area showed the infarcted size was significantly smaller in adult WT mice treated with Mydgf at 21 dpi relative to PBS (n = 25 for Mydgf-treated mice and n = 13 for PBS-treated mice). Scale bars, 500 µm. (D) Representative images of echocardiography analysis in adult WT mice treated with PBS/Mydgf at 21 dpi. (E) Echocardiography analysis of left ventricular ejection fraction (LVEF) in adult WT mice treated with PBS/Mydgf at 21 dpi (n = 19 for Mydgf-treated mice and n = 13 for PBS-treated mice). *P < 0.05 and **P < 0.01 compared to WT by Student's t-test (C and E). (F) Cumulative survival after MI in WT mice treated with 25 PBS and 20 Mydgf. *P < 0.05 compared to PBS-treated group by log-rank test. (G and H) Immunostaining illustrated proliferative (pH3⁺, green, white arrows) cardiomyocytes (CMs) were increased in WT adult mice treated with Mydgf relative to PBS at 7 dpi (n = 3 per group). (I and J) Immunostaining illustrated proliferative (Ki67⁺, green, white arrows) CMs were increased in WT adult mice treated with Mydgf relative to PBS at 7 dpi (n = 3 per group). (K and L) Immunostaining illustrated proliferative (Aurkb⁺, green, white arrows) CMs were increased in WT adult mice treated with Mydgf relative to PBS at 7 dpi (n = 3 per group). Scale bars, 20 µm. *P < 0.05 and **P < 0.01 compared to PBS-treated group by Student's t-test (H, J and L). Values were presented as the mean ± S.E.M.